Security key
097702203
Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT)
CUSIP: 097702203
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Shares outstanding
- 1,901,870
- Total 13F shares
- 613,252
- Share change
- +10,714
- Total reported value
- $2,488,203
- Price per share
- $4.04
- Number of holders
- 24
- Value change
- +$42,876
- Number of buys
- 9
- Number of sells
- 5
Report period
Q1 2026
Institutions
24
Top holders
10
BOLT full security history
Previous quarter: Q4 2025
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 097702203
Recent filing periods:
Top shareholders of BOLT - Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Pivotal bioVenture Partners Fund I, L.P. |
13D/G
|
Nan Fung Group Holdings Limited |
4.6%
|
87,486
|
$478,373 | -$222,181 | 24 Feb 2026 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
|
— |
3.5%
|
66,879
|
$355,790 | -$531,990 | 30 Sep 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
7.2%
|
137,721
|
$753,058 | — | 31 Dec 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
5%
|
94,573
|
$517,125 | — | 31 Dec 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3.8%
|
72,414
|
$395,960 | — | 31 Dec 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
3.1%
|
58,347
|
$319,041 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
2.9%
|
55,025
|
$300,877 | — | 31 Dec 2025 | |
| T3 Companies, LLC |
13F
|
Company |
2%
|
38,000
|
$207,784 | — | 31 Dec 2025 | |
| Board of Trustees of The Leland Stanford Junior University |
13F
|
Company |
1.9%
|
35,977
|
$196,722 | — | 31 Dec 2025 | |
| PFIZER INC |
13F
|
Company |
1.6%
|
31,305
|
$171,176 | — | 31 Dec 2025 | |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P |
13F
|
Company |
1.1%
|
20,500
|
$112,094 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.99%
|
18,803
|
$103,058 | — | 31 Dec 2025 | |
| Shay Capital LLC |
13F
|
Company |
0.8%
|
15,272
|
$83,507 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.54%
|
10,179
|
$55,782 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.51%
|
9,711
|
$53,100 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.16%
|
3,128
|
$17,104 | — | 31 Dec 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
723
|
$3,953 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
515
|
$2,816 | — | 31 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.01%
|
256
|
$1,403 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
42
|
$230 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
31
|
$169 | — | 31 Dec 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
10
|
$55 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
6
|
$33 | — | 31 Dec 2025 | |
| Vivo Capital VIII, LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
5,763,311
mixed-class rows
|
$5,435,517 | — | 21 Nov 2023 | |
| Novo Holdings A/S |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,703,991
|
$3,518,791 | — | 13 Jul 2022 | |
| Edgar Engleman |
3/4/5
|
Director |
—
mixed-class rows
|
2,098,005
mixed-class rows
|
$1,969,355 | — | 29 Nov 2023 | |
| Grant Yonehiro |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
398,918
mixed-class rows
|
$214,049 | — | 28 Jan 2026 | |
| Edith A. Perez |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
281,612
mixed-class rows
|
$36,451 | — | 04 Mar 2024 | |
| William P. Quinn |
3/4/5
|
President, CEO and CFO, Director |
—
mixed-class rows
|
722,313
mixed-class rows
|
$10,655 | +$1,262 | 28 Jan 2026 | |
| Randall C. Schatzman |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
247,859
mixed-class rows
|
$10,056 | — | 04 Mar 2024 | |
| Sarah Nemec |
3/4/5
|
Senior VP, Finance and PAO |
—
mixed-class rows
|
235,415
mixed-class rows
|
$6,518 | +$1,262 | 28 Jan 2026 | |
| David Dornan |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
210,000
|
— | — | 18 Feb 2022 | |
| Richard A. Miller MD |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 12 Jun 2023 | |
| Frank D. Lee |
3/4/5
|
Director |
—
class O/S missing
|
22,000
|
— | — | 12 Jun 2024 | |
| James Healy |
3/4/5
|
Director |
—
class O/S missing
|
22,000
|
— | — | 12 Jun 2024 | |
| Mahendra Shah |
3/4/5
|
Director |
—
class O/S missing
|
22,000
|
— | — | 12 Jun 2024 | |
| Brian O'Callaghan |
3/4/5
|
Director |
—
class O/S missing
|
1,100
|
— | — | 12 Dec 2025 | |
| Jakob Dupont |
3/4/5
|
Director |
—
class O/S missing
|
1,100
|
— | — | 12 Dec 2025 | |
| Kathleen Laporte |
3/4/5
|
Director |
—
class O/S missing
|
1,100
|
— | — | 12 Dec 2025 | |
| Laura Berner |
3/4/5
|
Director |
—
class O/S missing
|
1,100
|
— | — | 12 Dec 2025 | |
| Nicole Onetto |
3/4/5
|
Director |
—
class O/S missing
|
1,100
|
— | — | 12 Dec 2025 |
Institutional Holders of Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT) as of Q1 2026
As of 31 Mar 2026,
Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
613,252 shares.
The largest 10 holders included
Sofinnova Investments, Inc., RENAISSANCE TECHNOLOGIES LLC, Vivo Capital, LLC, Pivotal bioVenture Partners Investment Advisor LLC, T3 Companies, LLC, Board of Trustees of The Leland Stanford Junior University, Pfizer Inc, Lynx1 Capital Management LP, Nan Fung Group Holdings Ltd, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q1 2026 holders
24
Holder diff
3
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.